Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ASLN

ASLAN Pharmaceuticals Ltd ADR

Apr 18 • 09:43AM ET

0.5188

Dollar change +0.0278
Percentage change 5.66	%

Healthcare • Biotechnology • Singapore • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.75	Insider Own	3.48%	Shs Outstand	17.60M	Perf Week	-3.93%
Market Cap	9.13M	Forward P/E	-	EPS next Y	-2.42	Insider Trans	0.00%	Shs Float	16.99M	Perf Month	-26.92%
Income	-44.22M	PEG	-	EPS next Q	-0.61	Inst Own	19.79%	Short Float	0.69%	Perf Quarter	-2.04%
Sales	12.00M	P/S	0.76	EPS this Y	-34.57%	Inst Trans	-15.67%	Short Ratio	0.12	Perf Half Y	-59.78%
Book/sh	-0.76	P/B	-	EPS next Y	33.15%	ROA	-103.06%	Short Interest	0.12M	Perf Year	-85.98%
Cash/sh	1.21	P/C	0.43	EPS next 5Y	-	ROE	-426.64%	52W Range	0.39 - 4.69	Perf YTD	-0.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	17.51%	ROI	-384.13%	52W High	-88.94%	Beta	1.50
Dividend TTM	-	Quick Ratio	1.84	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	32.35%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	1.84	EPS Y/Y TTM	25.35%	Oper. Margin	-364.46%	RSI (14)	45.34	Volatility	9.89% 10.54%
Employees	35	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-368.50%	Recom	1.00	Target Price	9.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	24.70%	Payout	-	Rel Volume	0.58	Prev Close	0.49
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Apr 12 BMO	Avg Volume	985.78K	Price	0.52
SMA20	-9.95%	SMA50	-15.09%	SMA200	-58.34%	Trades		Volume	53,213	Change	5.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-09-21	Initiated	Jefferies	Buy	$8
Jan-14-19	Reiterated	H.C. Wainwright	Buy	$12 → $8.50

Apr-12-24 08:00AM	ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -7.37%
Apr-09-24 09:40AM	Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year? (Zacks)
Mar-27-24 08:07AM	Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders (GlobeNewswire)
Mar-12-24 02:34PM	ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering (GlobeNewswire) -57.98%
09:58AM	ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study (Zacks)
07:00AM	Loading…
Mar-11-24 07:00AM	ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients (GlobeNewswire) +160.80%
Mar-06-24 07:00AM	ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors (GlobeNewswire) +15.03%
Feb-29-24 07:00AM	ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat (GlobeNewswire) +25.71%
Jan-08-24 06:45AM	ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire) +27.13%
Jan-02-24 07:00AM	ASLAN Pharmaceuticals Announces Participation in January Investor Conferences (GlobeNewswire) +5.34%
Dec-12-23 07:00AM	ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs (GlobeNewswire) -6.93%
Nov-20-23 07:00AM	ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-03-23 07:00AM	ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit (GlobeNewswire)
Oct-27-23 08:00AM	ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -10.50%
Oct-24-23 08:00AM	ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis (GlobeNewswire)
07:00AM	Loading…
Oct-18-23 07:00AM	ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis (GlobeNewswire)
Oct-13-23 09:30AM	ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress (GlobeNewswire) -10.49%
Sep-22-23 07:00AM	ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-07-23 07:00AM	ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-11-23 07:00AM	ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-07-23 10:42AM	ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study (Zacks) -13.54%
Jul-06-23 11:09AM	What's Going On With ASLAN Pharmaceuticals Stock Today? (Benzinga) -24.41%
07:55AM	Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis (GlobeNewswire)
Jul-05-23 04:30PM	ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis (GlobeNewswire)
Jun-23-23 07:00AM	ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimabs Unique Mechanism of Action in the Treatment of Atopic Dermatitis (GlobeNewswire)
Jun-22-23 07:30AM	ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan (GlobeNewswire)
Jun-01-23 07:00AM	ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-18-23 07:00AM	ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata (GlobeNewswire)
May-15-23 07:00AM	ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting (GlobeNewswire)
Apr-28-23 07:00AM	ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
09:40AM	Loading…
Apr-27-23 09:40AM	Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-24-23 07:00AM	ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting (GlobeNewswire) +5.53%
Apr-05-23 09:40AM	Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year? (Zacks)
Mar-28-23 07:00AM	ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements (GlobeNewswire)
Mar-24-23 07:00AM	ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +5.82%
Mar-22-23 07:00AM	ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) -6.14%
Mar-20-23 09:40AM	Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-14-23 07:00AM	ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting (GlobeNewswire) +8.59%
Mar-13-23 07:54AM	ASLAN Pharmaceuticals Limited's (NASDAQ:ASLN) recent 25% pullback adds to one-year year losses, hedge funds owners may take drastic measures (Simply Wall St.) -10.19%
Mar-10-23 07:00AM	ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change (GlobeNewswire) -15.28%
Mar-09-23 09:55AM	Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now (Zacks)
Mar-08-23 07:00AM	ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata (GlobeNewswire)
Mar-02-23 09:40AM	Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-28-23 07:00AM	ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata (GlobeNewswire)
Feb-24-23 06:00AM	ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M (GlobeNewswire) +19.57%
05:59AM	ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients (GlobeNewswire)
Jan-03-23 07:00AM	ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies (GlobeNewswire) +20.88%
Dec-22-22 11:34AM	Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC (Zacks)
Dec-19-22 01:53PM	Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis (Zacks) -7.13%
Dec-16-22 07:00AM	ASLAN Pharmaceuticals Announces Participation in January Investor Conferences (GlobeNewswire)
Dec-15-22 07:00AM	ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients (GlobeNewswire) -8.18%
Nov-21-22 07:00AM	ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +5.38%
Nov-10-22 02:17PM	Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus (Zacks)
Nov-09-22 10:17AM	Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Nov-08-22 07:00AM	ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-28-22 07:00AM	ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-28-22 10:24AM	ASLAN Pharmaceuticals Presents New Data From Atopic Dermatitis Candidate (Benzinga)
07:00AM	ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting (GlobeNewswire)
Sep-14-22 11:05AM	ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients (Benzinga)
07:15AM	ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients (GlobeNewswire)
Sep-13-22 07:00AM	ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting (GlobeNewswire)
Sep-07-22 06:00AM	ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Sep-02-22 07:00AM	ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +6.52%
Aug-25-22 07:03AM	ASLAN PHARMACEUTICALS SIGNS LICENSE AGREEMENT WITH BELLE.AI TO USE BELLESTUDY IMAGE CAPTURE SOFTWARE IN ATOPIC DERMATITIS CLINICAL TRIALS (PR Newswire)
Aug-22-22 07:00AM	ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022 (GlobeNewswire)
Aug-12-22 07:00AM	ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +22.91%
Aug-11-22 07:00AM	ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire) +15.00%
Jun-07-22 07:00AM	ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis (GlobeNewswire)
Jun-06-22 07:00AM	ASLAN Pharmaceuticals to Host Third Webinar in A KOL Series: Dialogues With International Thought Leaders in Dermatology (GlobeNewswire)
May-31-22 07:00AM	ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-22 07:00AM	ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting (GlobeNewswire)
May-18-22 07:00AM	ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-10-22 07:00AM	ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual Meeting (GlobeNewswire) -6.02%
Apr-27-22 07:00AM	ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-06-22 07:00AM	ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022 (GlobeNewswire)
Apr-01-22 05:00PM	ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
Mar-28-22 07:00AM	ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-25-22 07:00AM	ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -6.22%
Mar-18-22 07:00AM	ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-15-22 07:00AM	ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer (GlobeNewswire) -9.03%
Jan-21-22 10:55AM	ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis (Zacks)
Jan-20-22 04:05PM	ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire) -5.03%
Jan-18-22 08:06AM	ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004 (GlobeNewswire) -8.33%
Jan-11-22 07:00AM	ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences (GlobeNewswire)
Jan-06-22 07:00AM	ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022 (GlobeNewswire)
Dec-06-21 07:00AM	ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration (GlobeNewswire) +10.57%
Nov-22-21 07:00AM	ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences (GlobeNewswire) -5.59%
Nov-10-21 07:00AM	ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th Annual Jefferies London Healthcare Conference 2021 (GlobeNewswire) -6.01%
Oct-26-21 07:00AM	ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +9.35%
Oct-22-21 07:00AM	ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr Emma Guttman-Yassky on Identification of ASLAN004-Specific Biomarkers (GlobeNewswire) -7.55%
Oct-18-21 07:00AM	ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004 (GlobeNewswire)
Oct-14-21 07:00AM	ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology (GlobeNewswire)
Sep-28-21 10:11AM	10 Best Healthcare Stocks Under $20 According to Michael Castors Sio Capital (Insider Monkey) -8.49%
Sep-27-21 02:30PM	Mid-Afternoon Market Update: Dow Gains 150 Points; Red Cat Holdings Shares Spike Higher (Benzinga) -34.77%
12:11PM	Mid-Day Market Update: Crude Oil Rises 2%; ASLAN Pharmaceuticals Shares Slide (Benzinga)
10:15AM	Mid-Morning Market Update: Markets Mixed; US Durable Goods Orders Increase Sharply In August (Benzinga)
06:00AM	ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis (GlobeNewswire)
Sep-22-21 07:00AM	ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-21-21 07:00AM	ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence Eichenfield (GlobeNewswire)
Sep-13-21 08:38AM	Implied Volatility Surging for ASLAN Pharmaceuticals (ASLN) Stock Options (Zacks)

Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASLN

ASLAN Pharmaceuticals Ltd ADR

Upgrade your FINVIZ experience